| R&D Projects |
Indications |
Status |
| HY3000 Nasal Spray |
Prevention & treatment of COVID-19 |
Phase III |
| HY3001 COVID-19 Peptide Vaccine |
Prevention of COVID-19 |
Preclinical |
| HY3003 GLP-1R/GIPR/GCGR Triple Agonist |
Diabetes mellitus & Weight loss & MASH |
Preclinical |
| Glatiramer Acetate Injection |
Multiple sclerosis |
Pending approval |
| Cetrorelix Acetate for Injection |
Assisted reproduction |
Pending approval |
| Teriparatide Injection |
Osteoporosis |
Pending approval |
| Carboprost Tromethamine Injection |
Postpartum hemorrhage |
Pending approval |
| Semaglutide Injection |
Diabetes mellitus & Weight loss |
Phase III |
| Abaloparatide Injection |
Osteoporosis |
FDF Process Validation |
| Teriparatide Acetate for Injection |
Osteoporosis |
FDF Process Validation |
| Difelikefalin acetate Injection |
CKD-Pruritus |
FDF Process Validation |
| Tirzepatide Injection |
Diabetes mellitus & Weight loss |
FDF Process Validation |
| Linaclotide Capsules |
IBS-C and CIC |
FDF Process Validation |
| Plecanatide Tablets |
IBS-C and CIC |
API Process Validation |
| Etelcalcetide Hydrochloride Injection |
CKD-Econdary hyperparathyroidism |
API Process Validation |
| Lanreotide Acetate Sustained-Release Injection |
Acromegaly |
API Process Validation |
| Semaglutide Tablets |
Diabetes mellitus & Weight loss |
API Process Validation |
| Sucrose Iron Hydroxide Chewable Tablets |
CKD-Related hyperphosphatemia |
R&D |
| Ferric Carboxymaltose Injection |
Iron deficiency anemia |
R&D |
| Pegcetacoplan Injection |
Geographic atrophy |
R&D |
